BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31430565)

  • 21. Evidence of rapid coaggregation of globular proteins during amyloid formation.
    Dubey K; Anand BG; Temgire MK; Kar K
    Biochemistry; 2014 Dec; 53(51):8001-4. PubMed ID: 25494036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxic Amyloid Tape: A Novel Mixed Antiparallel/Parallel β-Sheet Structure Formed by Amyloid β-Protein on GM1 Clusters.
    Okada Y; Okubo K; Ikeda K; Yano Y; Hoshino M; Hayashi Y; Kiso Y; Itoh-Watanabe H; Naito A; Matsuzaki K
    ACS Chem Neurosci; 2019 Jan; 10(1):563-572. PubMed ID: 30346704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of amyloid-β plaque formation by α-synuclein.
    Bachhuber T; Katzmarski N; McCarter JF; Loreth D; Tahirovic S; Kamp F; Abou-Ajram C; Nuscher B; Serrano-Pozo A; Müller A; Prinz M; Steiner H; Hyman BT; Haass C; Meyer-Luehmann M
    Nat Med; 2015 Jul; 21(7):802-7. PubMed ID: 26099047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous Human Proteins Interfering with Amyloid Formation.
    Gharibyan AL; Wasana Jayaweera S; Lehmann M; Anan I; Olofsson A
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural studies of amyloid-β peptides: Unlocking the mechanism of aggregation and the associated toxicity.
    Aleksis R; Oleskovs F; Jaudzems K; Pahnke J; Biverstål H
    Biochimie; 2017 Sep; 140():176-192. PubMed ID: 28751216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease.
    Tran J; Chang D; Hsu F; Wang H; Guo Z
    FEBS Lett; 2017 Jan; 591(1):177-185. PubMed ID: 27981583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease.
    Oskarsson ME; Paulsson JF; Schultz SW; Ingelsson M; Westermark P; Westermark GT
    Am J Pathol; 2015 Mar; 185(3):834-46. PubMed ID: 25700985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gallic acid oxidation products alter the formation pathway of insulin amyloid fibrils.
    Sakalauskas A; Ziaunys M; Smirnovas V
    Sci Rep; 2020 Sep; 10(1):14466. PubMed ID: 32879381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
    Kreutzer AG; Nowick JS
    Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease.
    Zerovnik E
    Eur J Biochem; 2002 Jul; 269(14):3362-71. PubMed ID: 12135474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological Basis for Amyloidogenesis in Alzheimer's Disease.
    Andreeva TV; Lukiw WJ; Rogaev EI
    Biochemistry (Mosc); 2017 Feb; 82(2):122-139. PubMed ID: 28320296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly potent intracellular membrane-associated Aβ seeds.
    Marzesco AM; Flötenmeyer M; Bühler A; Obermüller U; Staufenbiel M; Jucker M; Baumann F
    Sci Rep; 2016 Jun; 6():28125. PubMed ID: 27311744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E and amyloidogenesis.
    Frangione B; Castaño EM; Wisniewski T; Ghiso J; Prelli F; Vidal R
    Ciba Found Symp; 1996; 199():132-41; discussion 141-5. PubMed ID: 8915608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterotypic interactions in amyloid function and disease.
    Konstantoulea K; Louros N; Rousseau F; Schymkowitz J
    FEBS J; 2022 Apr; 289(8):2025-2046. PubMed ID: 33460517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The Convergence of Alzheimer's Disease Pathogenesis Concepts].
    Kozin SA; Makarov AA
    Mol Biol (Mosk); 2019; 53(6):1020-1028. PubMed ID: 31876280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of β-amyloid peptide in neurodegenerative diseases.
    Maltsev AV; Bystryak S; Galzitskaya OV
    Ageing Res Rev; 2011 Sep; 10(4):440-52. PubMed ID: 21406255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides Composed of Alternating L- and D-Amino Acids Inhibit Amyloidogenesis in Three Distinct Amyloid Systems Independent of Sequence.
    Kellock J; Hopping G; Caughey B; Daggett V
    J Mol Biol; 2016 Jun; 428(11):2317-2328. PubMed ID: 27012425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exogenous amyloidogenic proteins function as seeds in amyloid β-protein aggregation.
    Ono K; Takahashi R; Ikeda T; Mizuguchi M; Hamaguchi T; Yamada M
    Biochim Biophys Acta; 2014 Apr; 1842(4):646-53. PubMed ID: 24440525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.